GlassScriptPhysician profile
Nirali R Parikh
NPI 1831374172
$6,965.24
in general payments reported to CMS, 2019-2025
29 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.22 · 2020: $534 · 2021: $975 · 2022: $1,126 · 2023: $1,207 · 2024: $1,475 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,366.03 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $959.84 | 2020-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $858.82 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $517.29 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $508.17 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.34 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Corcept Therapeutics | $308.39 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $295.41 | 2023-2025 | Spravato, Xarelto |
| Abbvie INC. | $211.30 | 2023-2024 | |
| Amarin Pharma, INC. | $160.73 | 2021 | |
| Novartis Pharmaceuticals Corporation | $156.49 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $151.38 | 2024-2025 | Voquezna |
| Abbott Laboratories | $145.31 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $131.87 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $124.79 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $123.76 | 2022-2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $80.70 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $59.82 | 2019-2021 | |
| Exact Sciences Corporation | $58.11 | 2023-2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $52.21 | 2024-2025 | Edarbi |
| Esperion Therapeutics, INC. | $52.09 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $32.71 | 2021 | |
| Medtronic Minimed, INC. | $30.40 | 2020 | |
| Dexcom, INC. | $25.78 | 2021 | |
| Hologic Sales and Service, LLC | $24.10 | 2023 | Aptima |
| Echosens North America, INC. | $21.32 | 2025 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $18.07 | 2023 | Eliquis |
| Phadia US INC. | $16.45 | 2023 | Immunocap |
| Linus Health, INC. | $14.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirali Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.